232 related articles for article (PubMed ID: 35134811)
1. COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.
Martínez JC; Sica RA; Stockerl-Goldstein K; Rubinstein SM
Acta Haematol; 2022; 145(3):244-256. PubMed ID: 35134811
[TBL] [Abstract][Full Text] [Related]
2. Use of convalescent plasma in COVID-19 patients with immunosuppression.
Senefeld JW; Klassen SA; Ford SK; Senese KA; Wiggins CC; Bostrom BC; Thompson MA; Baker SE; Nicholson WT; Johnson PW; Carter RE; Henderson JP; Hartman WR; Pirofski LA; Wright RS; Fairweather L; Bruno KA; Paneth NS; Casadevall A; Joyner MJ
Transfusion; 2021 Aug; 61(8):2503-2511. PubMed ID: 34036587
[TBL] [Abstract][Full Text] [Related]
3. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.
Biernat MM; Kolasińska A; Kwiatkowski J; Urbaniak-Kujda D; Biernat P; Janocha-Litwin J; Szymczyk-Nużka M; Bursy D; Kalicińska E; Simon K; Mazur G; Wróbel T
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800528
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
Levy I; Lavi A; Zimran E; Grisariu S; Aumann S; Itchaki G; Berger T; Raanani P; Harel R; Aviv A; Lavi N; Zuckerman T; Shvidel L; Jarchowsky O; Ellis M; Herzog Tzarfati K; Koren-Michowitz M; Sherf Y; Levi I; Sofer O; Shpilberg O; Dally N; Suriu C; Braester A; Ben Barouch S; Leiba M; Goldstein D; Sarid N; Yeganeh S; Halloun J; Mittelman M; Tadmor T
Leuk Lymphoma; 2021 Dec; 62(14):3384-3393. PubMed ID: 34405767
[TBL] [Abstract][Full Text] [Related]
6. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside.
Laracy JC; Kamboj M; Vardhana SA
Curr Opin Infect Dis; 2022 Aug; 35(4):271-279. PubMed ID: 35849516
[TBL] [Abstract][Full Text] [Related]
7. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.
El Chaer F; Auletta JJ; Chemaly RF
Blood; 2022 Aug; 140(7):673-684. PubMed ID: 35776899
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Chien KS; Peterson CB; Young E; Chihara D; Manasanch EE; Ramdial JL; Thompson PA
Blood Adv; 2023 Oct; 7(19):5691-5697. PubMed ID: 36696472
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cattaneo C; Daffini R; Pagani C; Salvetti M; Mancini V; Borlenghi E; D'Adda M; Oberti M; Paini A; De Ciuceis C; Barbullushi K; Cancelli V; Belotti A; Re A; Motta M; Peli A; Bianchetti N; Anastasia A; Dalceggio D; Roccaro AM; Tucci A; Cairoli R; Muiesan ML; Rossi G
Cancer; 2020 Dec; 126(23):5069-5076. PubMed ID: 32910456
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of COVID-19 infection in Chinese patients with hematologic malignancies in the Omicron era.
Li X; Zhao A; Jiang H; Lu Y; Le J; Xie Y; Hu M; Zeng H; Zhao J; Zhou M; Zhou H; Chen L; Zhu W; Ouyang G; Qiu H; Jiang S; Guo Q; Qian W; Liang Y
Hematology; 2023 Dec; 28(1):2288477. PubMed ID: 38038062
[TBL] [Abstract][Full Text] [Related]
12. [SARS-COV-2 infection in patients with hematological malignancies and transplants].
Herrera F; Bues F; Rojas R; Temporiti E; Videla C; Dupont J; Bonvehí P
Medicina (B Aires); 2021; 81(3):396-400. PubMed ID: 34137699
[TBL] [Abstract][Full Text] [Related]
13. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
14. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.
Giesen N; Sprute R; Rüthrich M; Khodamoradi Y; Mellinghoff SC; Beutel G; Lueck C; Koldehoff M; Hentrich M; Sandherr M; von Bergwelt-Baildon M; Wolf HH; Hirsch HH; Wörmann B; Cornely OA; Köhler P; Schalk E; von Lilienfeld-Toal M;
Eur J Cancer; 2021 Apr; 147():154-160. PubMed ID: 33676266
[TBL] [Abstract][Full Text] [Related]
15. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
18. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
20. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
Morawska M
Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
